New-born Screening Disparity

Despite new-born screening being a critical driver of value and efficiency for patients and healthcare systems, there remains a vast disparity in diseases tested for across national panels

Incremental cost per QALY and evLY vs SoC

The US Institute for Clinical and Economic Review (ICER) uses equal value life year (evLY) to supplement the QALY in order to reduce the QALY’s discriminatory characteristics for those with a lower QoL

National Health Insurance Coverage in Nigeria

The impact of public healthcare insurance in Nigeria is expected to increase with the recent National Health Insurance Authority (NHIA) Act and commitment from all three presidential candidates to expand the National Health Insurance Scheme (NHIS)

Interactive Dashboard

We have launched our new Dashboard housing various applications, including our Automated Literature Review (ALR), Budget Impact Tool (BIM), COVID Tracker, Surveying platform and Value Network Visualisation (VNV). All of these applications, and many more, can be customised to your specific needs

US Medicare price negotiation

The US recently signed into law its historic Inflation Reduction Act, paving the way for public payer negotiation of pharmaceutical prices for specific Medicare drugs

NICE digital health assessment

NICE gave a positive recommendation for use to Sleepio and KardiaMobile in the areas of treatment of insomnia and detection of atrial fibrillation for people with suspected paroxysmal AF respectively.  Here is a breakdown of the digital health technology guidance thus far

Medical device software classification in Europe

With the ever growing number of medical device applications, we have summarised the European Commission guidance around health software to provide an indication of potential medical device software classification

Indirect quantitative research

Tired of the amount of time and resources indirect or quantitative research takes?  We are making conjoint and quantitative primary stakeholder research more efficient and accessible via our combined statistical, programming and consulting expertise.  This enables a rapid understanding of key factors affecting payer decision-making and clinician prescribing

What really is AI?

Given all the different terminologies and classifications related to artificial intelligence, we have created a visual summary to help distil value from the noise.  The pros and cons of each learning method and algorithm can vary, particularly depending on the problem being addressed

Diagnostic Value Simulation

With the growing focus on precision medicine and companion diagnostics, we recently simulated the proportional value of a diagnostic based its accuracy and the effectiveness of the corresponding treatment without the diagnostic in an interactive 3D graph


Chinese Drug Database

Our recently compiled database of the current and past National Essential Drugs Lists (NDRLs) in China enables easier querying and access to information.  The graphic below shows the increase in products across therapy areas.  Additional details are available upon request

3D RWE Study Graphic

Our novel 3D graphic on RWE study design can help simplify the complexity of brainstorming and planning studies.  Each potential study has 3 main axes for consideration, each with specific pros and cons, for which some are better suited than others depending on the overall objective

Value of Data Case Studies

Data is only as valuable as the context and method of the research, and in some cases, not valuable at all.  Understanding when and how to use what type of data can be challenging in today’s datacentric world

European Regulations on Digital Health

Is your organisation ready for the European Regulations on medical software/healthcare apps due to take effect?  With the growing number of digital health solutions in development, planning early for appropriate evidence requirements to ensure smooth CE marking and market access is critical

Vaccine Modelling

A key challenge in vaccine modelling is understanding the real-world reproduction number (R0), which is difficult to measure accurately for infectious diseases given the complexity around human contact patterns (although technological advances and predictive models are improving this).  For example, the commonly cited R0 for measles is 12-18 with wider reported ranges between 4.6-32.1.  This makes it extremely difficult to determine the threshold for herd immunity in order to stabilise the virus (1-1/R0), which could range from 92-94% if the R0 is between 12-18 or 78-97% if R0 is between 4.6-32.1.  Latest figures show the US and UK’s current MMR vaccination rate to be 91.5% and 91.2% respectively.  This means the real-world R0 for measles must be ≤11 to stabilise its spread.  However, increasing cases suggest R0 is moderately higher, which is a cause for concern

European Private Health Market

Did you know that private health spending in Europe accounts for 21% of total healthcare expenditure?  In addition, in most of the major markets, the average person spends more than €500 per year out-of-pocket?  This important market segment is well-suited for specific product types/attributes, as it is largely dependent on physician willingness-to-prescribe and patient willingness-to-pay

Have you seen the FDA’s recent Framework for real-world evidence (RWE) in regulatory decision-making?  We agree that pragmatic/hybrid/randomised RWE studies offer the greatest potential for regulatory efficacy/effectiveness decision-making.  However, until infrastructure and data standards improve to the point where a pragmatic RWE study is less costly and timely than the sum of its de facto components (clinical trial + set of prospective observational studies), it will be difficult to justify them from a commercial perspective.  We also agree that retrospective studies have substantial transparency issues and publication bias.  A mandatory protocol publication process for all retrospective studies within or a new domain (e.g. before any data analysis in order to be considered for any congress/journal publication could help to address these concerns

Did you know that the FDA recently made freely available the open source code for its MyStudies app?  The application can be downloaded and adapted by trial sponsors and sites to facilitate collection of real-world data directly from patients.  Not only can this save on trial set-up and monitoring costs, but it also ensures compliance with the FDA’s data protection regulations

Language »